Drug intelligence / Profile preview

strongylophorine-26

Development stage
Preclinical
Modality
Small Molecules
01

Overview

**Strongylophorine-26** is a meroditerpenoid natural product isolated from the marine sponge Petrosia corticata. It is characterized as a member of the diterpenoids, meroterpenoids, gamma-lactones, enol ethers, tertiary alcohols, and p-quinones. The compound has demonstrated antineoplastic effects, specifically inhibiting cancer cell invasion in vitro. Its architecture and configuration were confirmed by single-crystal X-ray diffraction and synthetic analog studies. This natural product is noted for its ability to suppress tumor cell migration and invasion, with the lactone moiety in its A ring being critical for biological activity. The first total synthesis and structure–activity relationship studies have been reported, but no clinical uses or pharmaceutical development are known.

Other names
strongylophorine-26strongylophorine26strongylophorine 26CHEBI:66527CHEMBL389231CHEMBL-389231CHEMBL 3892312-[[(1S,2S,5S,6S,7R,10R,11S)-5-hydroxy-5,7,11-trimethyl-12-oxo-13-oxatetracyclo[9.3.3.01,10.02,7]heptadecan-6-yl]methyl]-6-methoxycyclohexa-2,5-diene-1,4-dione2-{[(13alpha,14beta)-13-hydroxy-8,13-dimethyl-15-oxo-15,17-epoxypodocarpan-14-yl]methyl}-6-methoxycyclohexa-2,5-diene-1,4-dione

Beyond the preview

Go deeper on strongylophorine-26.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on strongylophorine-26.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call